The VA Launches Largest-Ever Trial on Screening Methods for Liver Cancer
The largest clinical trial in history related to liver cancer screening is launching in 2023, funded by the Department of Veterans Affairs. The project is scheduled to recruit 4,700 veterans with cirrhosis from 47 VA medical centers. Cirrhosis is a major risk factor for liver cancer and affects veterans disproportionally.
Congress Should Take This Chance to Fix Clinical Trial Diversity
Yale School of Medicine’s Jennifer Miller, Reshma Ramachandran, and Tanvee Varma say Congress should advance clinical trial diversity and social justice in its year-end spending bill. Clinical trials usually underrepresent women, older adults, and minorities, creating uncertainty about drug safety, they say.Source: Bloomberg Law
Bypass Surgery Has Lower Risks Than Endovascular Therapy for Limb-threatening Ischemia
Bypass surgery in artiries leading to the legs was associated with a lower risk of cardiac events among patients with peripheral arterial disease who are candidates for two types of revascularization therapy, new research suggests.
No Survival Advantage for Either Torsemide or Furosemide in HF: TRANSFORM-HF
The choice of loop diuretic for decongestion in patients hospitalized with heart failure (HF) may make little difference to survival or readmission risk over the next year, at least when deciding between furosemide or torsemide, a randomized trial suggests.Source: Medscape
TRANSFORM-HF: Loop Diuretics Show No Difference in Mortality and Hospitalizations for Heart Failure
The results of the TRANSFORM-HF study, which explored the effects of two different therapies on heart failure outcomes, were featured during the first late-breaking session at the American Heart Association Scientific Sessions.
How targeted EHR alerts can close practice gaps and improve patient care: insights from an expert at Yale School of Medicine
Although heart disease has long been known a leading cause of morbidity worldwide, it takes too long for evidence-based research to translate into direct patient care when it comes to pharmaceutical therapies.Source: Becker's Hospital Review
Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support
Outcomes included in-hospital survival, myocardial infarction (MI), cardiogenic shock, stroke, bleeding requiring transfusion, acute kidney injury, index hospitalization length of stay, and costs.Source: Business Wire
Impella heart pumps linked to improved high-risk PCI outcomes
High-risk percutaneous coronary intervention (PCI) with an Impella heart pump is associated with better outcomes, including a significantly higher survival rate, than high-risk PCI with an intra-aortic balloon pump (IABP).Source: Cardiovascular Business
Fighting Breast and Ovarian Cancer With a Lupus Antibody
After discovering a specific lupus antibody that can penetrate cancer cells and, with a grant from Women's Health Research at Yale, showing it makes cancer cells vulnerable to standard treatments, Dr. Peter Glazer and his colleagues are moving a treatment to clinical trials.
Is IVL equally effective in male and female patients? Shockwave Medical aims to find out with a historic new study
Shockwave Medical has announced a new clinical trial focused on the safety and effectiveness of its intravascular lithotripsy (IVL) technology in female patients.Source: Cardiovascular Business
Improving Adherence Among HF Patients: A Look at the PROMPT-HF Trial
The Pragmatic Trial of Messaging to Providers About Treatment in Heart Failure (PROMPT-HF) was designed to test the hypothesis that tailored and targeted electronic health record alerts recommending guideline-directed medical therapy (GDMT) for patients with heart failure (HF) would result in greater adherence to medication use.Source: ReachMD Radio
Provision of 1-year mortality data for patients hospitalized with heart failure does not influence clinical decision-making – The REVEAL-HF trial
No significant differences in targeted interventions occurred between patients with heart failure managed by clinicians with additional prognostic information compared to those without.Source: 2minutemedicine
Using Particles That Are Smaller Than the Head of a Pin to Treat Cancer
Thanks in part to research begun more than a decade ago with funding from Women’s Health Research at Yale, Dr. W. Mark Saltzman is working with colleagues on a way to deploy effective cancer-fighting medication safely with the help of nanoparticles.
New technology could be game changer for people living with Type 1 diabetes
There's a new high-tech tool that could be a game-changer for people with Type 1 diabetes. Yale Principal Investigator and Associate Professor in Pediatrics (Endocrinology), Jennifer Sherr, discusses the Omnipod 5, which monitors insulin levels through a sensor on the skin, then sends the insulin directly through the patch as needed.Source: WNYT.com